Growing Coronavirus Testing Turns Quest Diagnostics Analyst Bullish

Quest Diagnostics Inc DGX  preannounced its second-quarter revenue at around $1.83 billion on Monday, beating Street estimates by about 18%. Preliminary also came in ahead, in the range of $1.39-$1.42 per share versus the Street’s 18-cent estimate. 

The company’s second-quarter earnings were driven by a faster recovery in core testing volumes and growing COVID-19 testing services, according to BofA Securities.

The Quest Diagnostics Analyst: Derik de Bruin upgraded Quest Diagnostics from Neutral to Buy and raised the price target from $124 to $142.

The Quest Diagnostics Thesis: Coronavirus testing tailwinds are likely to last longer than was previously anticipated, de Bruin said in a Tuesday upgrade note. (See his track record here.)

The analyst named the reasons for the prolonged tailwinds as:

  • Deteriorating coronavirus situation in the U.S.
  • Uncertainties around when a vaccine can be approved
  • Doubts around herd immunity developing
  • Potential for repeated waves of the virus

“We are still skeptical on serology testing and continue to assume a lower utilization rate, but we expect molecular testing (MDx) demand and utilization should continue at a high level,” de Bruin said. 

The analyst raised the revenue estimates for fiscal 2021 and 2022 from $7.542 billion to $8.134 billion and from $8.110 billion to $8.825 billion, respectively. BofA also raised the earnings estimates for the years from $4.20 per share to $6.30 per share and from $7.60 per share to $8.40 per share, respectively.

DGX Price Action: Shares of Quest Diagnostics were trading 0.77% higher to $120.06 at last check.

Related Links:

Benzinga's Top Upgrades, Downgrades For July 14, 2020

Moderna, Other Vaccine Developers Lead The Way In New GERM ETF

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: Analyst ColorEarningsNewsUpgradesHealth CarePrice TargetAnalyst RatingsGeneralBofA SecuritiesCoronavirusCovid-19Derik de Bruin
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!